Docstoc

Immunotherapy

Document Sample
Immunotherapy Powered By Docstoc
					Immunotherapy
  Personal statistics

 John Weisnagel, M.D.
                       Database
   Sept 1992-June 2006: 23,577 patients
   Undergoing immunotherapy: 2,393 pts
    (10.14%)
       Perennial Rx (all-year long): 1,437 (60%)
       Pre-seasonal Rx (one injection per week 1-2
        months preceding the specific pollen season):
        936 (39.1%)
                 20 pts having rec’d both types of treatment.
    Efficacy of immunotherapy
   Of the 2,393 treated since 1992,
   983 replied to the question of the effect of
    their treatment (excellent, very good,
    good, slight or no change) when reminders
    were sent them about renewals
       Treatment was either:
          Perennial or
          Pre-seasonal.
           Perennial Treatment
   581 patients:
       Asthma:                 53 (9.12%)
       Asthma + pollinosis:    74 (12.7%)
       Asthma + rhinitis:      83 (14.2%)
       Pollinosis:            148 (25.47%)
       Rhinitis:              223 (38.38%)
     Efficacy of Perennial treatment in 581 patients

             Excellent   Very good     Good       Slight    Ineffective

 Asthma
             4 (7.5%)    17 (32%)    15 (28.3%) 7 (13.2%) 10 (18.8%)
   53
Asthma +
pollinosis   7 (9.4%)    19 (25.6%) 24 (32.4%) 14 (18.9%) 10 (13.5%)
   74
Asthma +     5   (6%)    25 (30.1%   18 (21.6%) 23 (27.7%) 12 (14.4%)
 rhinitis
  83
Pollinosis   20 (13.5%) 54 (36.4%) 50 (33.7%) 16 (10.8%) 8      (5.4%)
  148
 Rhinitis    21 (9.4%) 64 (28.6%) 62 (27.8%) 53 (23.7%) 23 (10.3%)
  223
        Pre-seasonal Treatment
   402 patients:
       Asthma + pollinosis:     6      (1.4%)
       Asthma + rhinitis:       2     (0.49%)
       Pollinosis:            393   (97.76%)
       Rhinitis:                1     (0.29%)
   Efficacy of pre-seasonal treatment in 402 patients

             Excellent   Very good     Good          Slight    Ineffective

Asthma &
pollinosis   3   (50%)   1 (16.6%)   1 (16.6%)         0       1 (16.6%)
     6
Asthma &
 rhinitis    1   (50%)      0           0        1     (50%)       0
     2
Pollinosis
             79 (20.1%) 134 (34%) 110 (27.9%) 47 (11.9%)       23 (5.8%)
   393

 Rhinitis
                 0       1 (100%)       0              0           0
    1
                           Totals
            Excellent   Very good   Good    Slight   Ineffective

Perennial     9.8%       30.8%      29%     19.4%      10.8%




  Pre-
             20.6%       33.8%      27.6%   11.9%      5.9%
seasonal
                 Efficacy summary
35

30

25

20                                         Pernneial
                                           Pre-seasonal
15

10

 5

 0
     Excellent       Good    Ineffective
                Pre-seasonals
   Center-Al™
   Suspal™
   Pollinex R™
       Other tyrosine preps.
                   Perennials
   Mixtures:
       House dust mite + pollens
       House dust mite + molds
       House dust mite + pollens + molds
                  Bottom line
   These personal statistics, though anecdotal,
    reflect the conclusion of the many studies
    published on the benefit of immunotherapy.
   Both forms of therapy, perennial and pre-
    seasonal have similar benefits.
   Immunotherapy is still an effective treatment in
    respiratory allergy, and should be considered
    when pharmaceutical therapy is inadequate.

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:3
posted:10/10/2011
language:English
pages:12